Lynparza for Ovarian Cancer (Resubmission) – Details


( Last Updated : October 5, 2017)
Generic Name:
Olaparib
Project Status:
Complete
Therapeutic Area:
Ovarian Cancer
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Lynparza (Resubmission)
Project Line:
Reimbursement Review
Project Number:
PC0103-000
NOC Date:

Details


Strength:
50 mg capsules
Tumour Type:
Gynecology
Indications:
Ovarian Cancer
Funding Request:
As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy
Review Status:
Complete
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.